International Journal of Clinical Oncology最新文献

{"title":"Systematic review and meta-analysis of photon radiotherapy versus proton beam therapy for pediatric rhabdomyosarcoma: TRP-rhabdomyosarcoma 2024.","authors":"Hiroko Fukushima, Masashi Mizumoto, Sho Hosaka, Yinuo Li, Kazushi Maruo, Yoshiko Oshiro, Hazuki Nitta, Takashi Iizumi, Takashi Saito, Masako Inaba, Ryoko Suzuki, Kei Nakai, Shosei Shimizu, Hideyuki Sakurai","doi":"10.1007/s10147-025-02794-2","DOIUrl":"10.1007/s10147-025-02794-2","url":null,"abstract":"<p><strong>Background: </strong>Childhood cancer treatment has increasingly achieved favorable long-term survival rates, shifting focus toward reducing long-term comorbidities. Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue tumor, and radiation therapy is essential for its treatment. Proton beam therapy (PBT) is currently utilized due to its potential to reduce long-term complications; however, data on its impact on tumor prognosis remain limited.</p><p><strong>Methods: </strong>We conducted a meta-analysis to evaluate whether differences in tumor prognosis exist based on radiation therapy modalities, such as photon radiotherapy (photon RT) and PBT, for pediatric parameningial RMS-only study (Group 2) and other pediatric RMS (Group 1). Studies published between 1990 and 2022 were included if they were written in English, included more than 10 cases, and reported outcomes such as overall survival (OS) and local control rates (LC).</p><p><strong>Results: </strong>A total of 37 results (photon RT: 23, PBT: 14) were analyzed using random-effects meta-analyses. No significant differences were observed between treatment modalities in 1- to 5-year OS (photon RT vs. PBT) in Group 1. Early (1- and 3-year) inferior LC rates were observed with PBT in Group 2.</p><p><strong>Discussion and conclusion: </strong>Overall survival or LC rates don't differ significantly between cases treated with photon RT and those treated with PBT. The inferior early LC rates in cases of parameningeal-only RMS study treated with PBT may be attributed to the limited number of studies describing PBT, many of which were single-center reports. Unbiased clinical trial data are needed to clarify differences in early local relapses in parameningeal RMS.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1670-1677"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors.","authors":"Toshio Kubo, Hironari Kato, Shigeru Horiguchi, Toshiyuki Kozuki, Akinori Asagi, Michihiro Yoshida, Heiichiro Udono, Katsuyuki Kiura, Katsuyuki Hotta","doi":"10.1007/s10147-025-02786-2","DOIUrl":"10.1007/s10147-025-02786-2","url":null,"abstract":"<p><strong>Background: </strong>Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse models. Therefore, we conducted a phase Ib study using combination therapy with nivolumab and metformin in patients with refractory/recurrent solid tumors.</p><p><strong>Methods: </strong>This study consisted of two parts: 1, evaluating the maximum tolerated dose (MTD), safety, pharmacokinetics in solid tumors, and 2, principally investigating the safety at the recommended dose limited to thoracic and pancreatic cancers. Metformin and nivolumab were administered orally at doses of 750-2,250 mg/day and biweekly at a fixed intravenous dose of 3 mg/kg, respectively. Dose-limiting toxicity was evaluated within the first 4 weeks. Both metformin and nivolumab were continued until disease progression or discontinued because of toxicity.</p><p><strong>Results: </strong>In total, 17 and 24 patients were enrolled in parts 1 and 2, respectively. One patient experienced increased pancreatic enzyme levels (grade 4) and lactic acidosis (grade 3). No Grade 5 adverse events were observed. MTD was not reached up to 2,250 mg/day of metformin, 2,250 mg/day was selected for part 2. An objective response was observed in 4 of 41 patients. One-year progression-free and overall survival rates were 9.8% and 56.8%, respectively. Two patients remained alive without disease progression for more than three years.</p><p><strong>Conclusions: </strong>Nivolumab and metformin combination therapy was well-tolerated and showed preliminary signals of efficacy in a subset of patients. Further verification of the underlying mechanism in cases where treatment is effective is required.</p><p><strong>Trial registration numbers: </strong>UMIN registration number 000028405 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031915 .</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1537-1544"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.","authors":"Margaret Shatara, Nicole M Brossier, Andrew Cluster, Ali Y Mian, Sonika Dahiya, Amy E Armstrong, Angela C Hirbe, David H Gutmann, Kenneth Aldape, Mohamed S Abdelbaki","doi":"10.1007/s10147-025-02793-3","DOIUrl":"10.1007/s10147-025-02793-3","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.</p><p><strong>Methods: </strong>The tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.</p><p><strong>Results: </strong>From January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).</p><p><strong>Conclusion: </strong>This initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1659-1669"},"PeriodicalIF":2.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors.","authors":"Kei Muro, Kentaro Yamazaki, Shigenori Kadowaki, Saori Mishima, Takeshi Kawakami, Tomoyuki Tanaka, Keisuke Tada, Nathalie Fagniez, Shinobu Ohshima, Takayuki Yoshino","doi":"10.1007/s10147-025-02784-4","DOIUrl":"10.1007/s10147-025-02784-4","url":null,"abstract":"<p><strong>Background: </strong>Tusamitamab ravtansine (SAR408701) is an immunoconjugate that binds carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers its cytotoxic payload to target cells. Here, we report findings from three dosing regimens of tusamitamab ravtansine administration in Japanese adults with advanced malignant solid tumors.</p><p><strong>Methods: </strong>Japanese adults (aged ≥ 20 years) with CEACAM5-expressing malignant solid tumors were enrolled in this Phase 1, open-label, non-randomized, dose-escalation evaluation of tusamitamab ravtansine in three parts: (i) main dose-escalation part with every two weeks (Q2W) administration, (ii) loading dose (LD) part with Q2W administration with a LD at Cycle 1 (C1) only, and (iii) dose-escalation every three weeks (Q3W) part. Primary objectives were to evaluate the tolerability and safety of tusamitamab ravtansine.</p><p><strong>Results: </strong>Nine patients were enrolled in the main dose-escalation part, 16 patients in the dose-escalation bis part with LD, and nine patients in the dose-escalation Q3W part. Administration of tusamitamab ravtansine resulted in a manageable safety profile with no dose-limiting toxicities reported during the observation period except for two events during dose-escalation bis Q2W part. Most common adverse events (AEs) were corneal events, gastrointestinal disorders, and metabolic events. After first administration, tusamitamab ravtansine exposure was dose proportional over the dose range 80-170 mg/m². Best overall response (BOR) was stable disease, observed in all three parts; confirmed response was not observed at any dose level.</p><p><strong>Conclusion: </strong>Tusamitamab ravtansine demonstrated a tolerable safety profile at a dose of 80-170 mg/m² in three different administration schedules in Japanese adults with metastatic solid tumors.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1522-1536"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT).","authors":"Yohei Iimura, Hiroshi Ishiguro, Hironobu Hashimoto, Masanori Nojima, Shunsuke Oyamada, Keita Mori, Keisuke Ariyoshi, Seiichiro Kuroda, Satoshi Hirakawa, Noriko Fujiwara, Tomoya Yokota, Sadamoto Zenda, Hiromichi Matsuoka, Narikazu Boku","doi":"10.1007/s10147-025-02789-z","DOIUrl":"10.1007/s10147-025-02789-z","url":null,"abstract":"<p><strong>Background: </strong>Clinical evidence on preventive therapy for capecitabine-induced hand-foot syndrome (HFS) is limited, and moisturizing and avoiding local pressure are recommended in guidelines. Although the precise pathogenesis and mechanisms of HFS remain unclear, inflammatory reactions are thought to be involved. The preventive effects of topical diclofenac gel have been reported from India. However, the trial did not evaluate its preventive effect for the sole, and the HFS incidence in the control group was lower than that in previous reports. Therefore, this study aims to confirm the preventive effects of diclofenac sodium 0.1% cream for capecitabine-induced HFS.</p><p><strong>Methods: </strong>This is a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Patients scheduled to receive capecitabine-containing chemotherapy are enrolled, and participants are prophylactically treated with topical diclofenac sodium 0.1% cream or placebo alongside standard preventive therapy. The primary endpoint is an incidence of grade 2 HFS within 3 months. The secondary endpoints include time to onset of HFS, incidences of dose reduction, schedule delay, discontinuation caused by capecitabine-induced HFS, dose intensity of capecitabine, an incidence of grade ≥ 2 peripheral sensory neuropathy, incidences of other capecitabine-related adverse events (nausea, vomiting, appetite loss, diarrhea, oral mucositis, pigmentation, abnormality of liver and renal functions, and neutropenia).</p><p><strong>Discussion: </strong>If this study meets the primary endpoint, a new standard preventive therapy for HFS will be established. Moreover, the use of topical diclofenac cream alongside high-dose capecitabine may enhance chemotherapy efficacy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1553-1561"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of vaginal cytology for postoperative surveillance of endometrial cancer.","authors":"Yuko Watanabe, Eiji Kobayashi, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Kosuke Hiramatsu, Tadashi Iwamiya, Shinya Matsuzaki, Eiji Nakatani, Yutaka Ueda","doi":"10.1007/s10147-025-02843-w","DOIUrl":"https://doi.org/10.1007/s10147-025-02843-w","url":null,"abstract":"<p><strong>Background: </strong>The value of conducting vaginal cytology surveillance after endometrial cancer (EC) surgery has not been fully established, yet in Japan it is still performed routinely in many institutions. We have retrospectively examined its diagnostic and prognostic values.</p><p><strong>Methods: </strong>We studied 759 EC cases that underwent hysterectomy at our hospital in Osaka, Japan from January 2010 to December 2019. Information on the clinicopathological factors at the time of initial and postoperative treatments, and the sites and diagnostic timing of recurrences were extracted from medical records and analyzed.</p><p><strong>Results: </strong>Recurrences from primary EC were observed in 11.2% of the patients (85/759). In 23.5% of the cases (20/85), the recurrence included a vaginal component. The two most common single-sites of recurrence were vagina (14.1%, 12/85) and lung (12.9%, 11/85). The diagnosis of vaginal recurrence was made from symptoms and gynecological examination in 14 of the 20 cases. Only one was diagnosed solely by vaginal cytology; in that case, macroscopic lesions appeared two months after obtaining the abnormal cytology.</p><p><strong>Conclusions: </strong>We found that, in postoperative follow-up surveillance for EC, most cases of vaginal recurrence were first diagnosed by a careful pelvic examination. For current routine postoperative practice, monitoring critical symptoms and conducting careful gynecological examinations has been shown to be more important than cytological examinations.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of long‑term survival in patients with stage IV colorectal cancer with primary tumor resection: a multi-center retrospective analysis.","authors":"Kiyoaki Sugiura, Tatsuki Kato, Junya Aoyama, Go Oshima, Hiroto Kikuchi, Koji Okabayashi, Satoshi Aiko, Yuko Kitagawa","doi":"10.1007/s10147-025-02845-8","DOIUrl":"https://doi.org/10.1007/s10147-025-02845-8","url":null,"abstract":"<p><strong>Background: </strong>Primary tumor resection is an option for patients with stage IV colorectal cancer (CRC). However, there is still no reliable strategy for predicting the survival of individual patients undergoing primary tumor resection (PTR). The aim of this study was to identify predictors of good prognosis in patients with stage IV CRC with PTR.</p><p><strong>Methods: </strong>This is a retrospective analysis of patients with stage IV CRC who had undergone PTR in the Keio Surveillance Epidemiology and End Results (K-SEER) database. Clinical data and short- and long-term outcomes were analyzed. Univariate and multivariate analyses were performed using Cox proportional hazards model including all survival-related variables.</p><p><strong>Results: </strong>Among 252 patients enrolled in this study, 176 had single-organ and 76 had multi-organ metastases. Seventy-seven patients did not receive chemotherapy after primary tumor resection. Three patients consequently underwent curative metastasectomy after PTR. Multivariate Cox analysis revealed age, number of organs with metastasis, and chemotherapy after PTR were independently associated with both Overall Survival (OS) and Cancer-Specific Survival (CSS). In the subgroup analysis, the survival rate was significantly lower in patients with multi-organ metastases than in those with single-organ metastases, both in 3-year OS (47.69% vs 23.20%; log-rank P < 0.001) and 3-year CSS (54.45% vs 30.48%; log-rank P < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated that multi-organ metastasis was a prognostic factor for poor prognosis in patients with stage IV CRC patients who underwent PTR. These findings could support surgeons to make better clinical decisions for patients with stage IV CRC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Metazoan SpoT Homolog 1 promotes ferroptosis by regulating the intracellular redox cycle and iron levels in hepatocellular carcinoma.","authors":"Yuki Nakayama, Shinji Itoh, Takeo Toshima, Kyohei Yugawa, Shohei Yoshiya, Norifumi Iseda, Yuriko Tsutsui, Katsuya Toshida, Takuma Ishikawa, Tomoharu Yoshizumi","doi":"10.1007/s10147-025-02818-x","DOIUrl":"https://doi.org/10.1007/s10147-025-02818-x","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, a form of programmed cell death, is a potential target for cancer therapy. Metazoan SpoT Homolog 1 (MESH1) possesses intracellular NADPH phosphatase activity, which has been linked to ferroptosis. However, the molecular effects on the ferroptosis in hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate the relationship between MESH1 expression and the prognosis of patients with HCC, as well as its impact on ferroptosis in HCC cells.</p><p><strong>Methods: </strong>We used resected specimens from patients to assess the relationship between MESH1 expression and prognosis. HCC cell lines were used to evaluate the impact of MESH1 expression on the cell phenotype and ferroptosis through various assays, RNA sequencing, and an animal experiment with xenograft mice model.</p><p><strong>Results: </strong>We found that high MESH1 expression correlated with good outcomes. Further investigation demonstrated that MESH1 also exhibits NADPH phosphatase activity in HCC, contributing to increased sensitivity to ferroptosis when the ferroptosis inducer was used. Similar results were observed with other ferroptosis inducers, sorafenib and lenvatinib. Notably, RNA sequencing analysis of cells with MESH1 KD revealed a correlation between intracellular iron homeostasis and MESH1 levels. These results suggested that MESH1 also can affect ferroptosis sensitivity through changing intracellular iron levels. Tumors derived from MESH1 KD cells in xenograft mice showed reduced sensitivity to sorafenib and lenvatinib, further supporting the role of MESH1 ferroptosis regulation.</p><p><strong>Conclusion: </strong>This study suggests that MESH1 influences intracellular redox and iron regulatory pathways, both of which are linked to cellular processes associated with ferroptosis.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of clinical features by primary site in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113.","authors":"Yuko Suzuki, Masafumi Ikeda, Junki Mizusawa, Yusuke Sano, Chigusa Morizane, Takuji Okusaka, Satoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Naohiro Okano, Haruo Miwa, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Sohei Satoi, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Masato Ozaka, Makoto Ueno","doi":"10.1007/s10147-025-02834-x","DOIUrl":"https://doi.org/10.1007/s10147-025-02834-x","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancers (BTCs) are heterogenous malignancies including gallbladder cancer (GBC), intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and ampulla of Vater cancer (AVC). The reported data about the differences between the primary sites are limited to data that have just evaluated the efficacy of the treatment arms by primary site in randomized controlled trials. We aimed to compare the clinical features and treatment efficacy among the primary sites of BTCs using data from JCOG1113, a randomized trial.</p><p><strong>Methods: </strong>Among the 354 patients enrolled in JCOG1113, 352 patients were included in this analysis. We compared the patient characteristics, and efficacy outcomes among the primary sites.</p><p><strong>Results: </strong>There were more women (58.4%), and more patients with metastatic disease (78.1%) and multiple organs involving metastases (49.3%) in GBC compared to other primary sites. The median progression-free survival (PFS) was 5.7 months, 6.2 months, 8.7 months and 4.1 months for GBC, IHCC, EHCC and AVC, respectively. The median OS was 12.6 months, 15.7 months, 16.3 months and 11.5 months for GBC, IHCC, EHCC and AVC, respectively. Multivariable analysis revealed that GBC was identified as one of the prognostic factors for PFS compared with EHCC but was not significant for OS.</p><p><strong>Conclusions: </strong>In this study, there were several findings regarding the differences in the clinical features, treatment efficacy, and prognosis among the primary sites. Patients with GBC were more likely to have metastatic disease and multiple metastases. GBC was an independent prognostic factor for PFS compared with EHCC, but was not for OS.</p><p><strong>Clinical trial registration: </strong>JCOG1113 was registered with University hospital Medical Information Network Clinical Trials Regisry (UMIN000010667).</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of prior COVID-19 infection on perioperative outcomes in non-small cell lung cancer patients: a prospective observational cohort study.","authors":"Hanbo Pan, Fan Shen, Ningyuan Zou, Yu Tian, Jiaqi Zhang, Yixing Tao, Hongda Zhu, Jia Huang, Qingquan Luo","doi":"10.1007/s10147-025-02836-9","DOIUrl":"https://doi.org/10.1007/s10147-025-02836-9","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 infection may induce persistent pulmonary sequelae, potentially elevating perioperative risks in non-small cell lung cancer (NSCLC) patients. This study aims to evaluate the impact of prior COVID-19 infection on perioperative outcomes in NSCLC patients undergoing lung resection.</p><p><strong>Methods: </strong>This prospective observational cohort study enrolled NSCLC patients undergoing surgery at Shanghai Chest Hospital (May 2024-January 2025). Patients were stratified into COVID-19-exposed (PCOV) and non-exposed (NCOV) cohorts. The primary endpoint: 30-day postoperative pulmonary complications (PPCs); secondary endpoints: surgical duration and postoperative hospital stay. Propensity-score matching (PSM; 1:1 ratio) was performed to address confounders.</p><p><strong>Results: </strong>Among 2285 enrolled patients (NCOV: 913; PCOV: 1372), PSM yielded 762 matched pairs with balanced baseline characteristics. The PCOV group exhibited significantly higher 30-day PPC rates (Unmatched: 18.0% vs. 10.4%, P < 0.001; Matched: 17.3% vs. 10.8%, P < 0.001), prolonged surgical durations (Unmatched: 108.6[86.0-128.2] vs. 123.6[93.7-139.0], P < 0.001; Matched: 111.8[87.4-129.1] vs. 121.1[92.8-138.2], P < 0.001; mins, median[interquartile range(IQR)]) and extended postoperative hospital stays (Unmatched: 4[4-5] vs. 5[4-6], P < 0.001; Matched: 4[4-5] vs. 5[4-6], P < 0.001; days, median[IQR]) compared to the NCOV group. Other perioperative outcomes were comparable between the groups. Stratified analyses demonstrated elevated 30-day PPC risk in all predefined PCOV subgroups except patients aged ≤ 65 years (Unmatched: 1.312[0.919-1.873], P = 0.135; Matched: 1.302[0.846-2.004], P = 0.230; odds ratio [95% confidence interval]). Further analysis for patients aged ≤ 65 years showed that the PCOV group exhibited no significant differences in perioperative outcomes compared to the NCOV group, except for surgical duration.</p><p><strong>Conclusion: </strong>Prior COVID-19 infection is associated with increased PPCs, longer operative times, and delayed discharge in NSCLC patients. However, perioperative outcomes remained comparable in patients ≤ 65 years, suggesting age-dependent resilience to COVID-19-related surgical risks.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}